ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2020
Effect of
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- Hepato-Renal Protective Potential of Dimethyl Fumarate in Alloxan-Induced Diabetic Mice Model by Modulating of Sirt1, Nrf2 and Inflammatory Genes Expressions.Endocrinology, diabetes & metabolism · 2026Article
- Review
- Exploring Therapeutic Potential ofFoods (Basel, Switzerland) · 2024Article
- Effect of heterologous platelet-rich plasma on liver and modulation of glucose metabolism and Wnt signalling pathways in diabetic mice.Molecular biology reports · 2023Article
- Evaluation ofDisease markers · 2023Article
- Antioxidant and antidiabetic activities of a polyphenol rich extract obtained fromFrontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe antidiabetic effects of the
methodsThe albino Wistar rats were divided into five groups with six animals in each. Group, I, II, and III were normal, diabetic, and drug control, respectively, and groups IV and V were test groups. As treatment dose, group II received saline, and group III (drug control) received metformin in 100 mg/kg of body weight as a standard drug. Whereas, group IV (D1) and V (D2) were test groups, received PFA-extract in 250 mg/kg, and 500 mg/kg of body weight, respectively. The changes in body weight, blood glucose level (BGL), lipid profile, liver, and kidney biochemical parameters were evaluated.
resultsThe PFA-extract dose at 500 mg/kg in D2 groups showed very good effects. The body weight was recovered by 97.9% and blood glucose level (BGL) was reduced to 53% in the D2 group. For the lipid profile, total cholesterol (TC), triglyceride (TG), and high-density lipoprotein (HDL) were estimated in blood plasma and their values were 92.31±3.788, 80.85±8.962, and 31.35±1.781, respectively. PFA-extract improved the liver function for which aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were evaluated and recorded to their normal range in D2 group which were 132.01±5.553, 58.63±4.390, and 143.26±2.423, respectively. For the kidney function test, creatinine (CRT), blood urea nitrogen (BUN), and uric acid were evaluated and in the D2 group, it was significantly reduced ie, 0.656±0.0707, 15.13±1.463, and 6.27±0.325, respectively.
conclusionThese attributes of PFA-extract make it a potential natural agent to provide protection to the liver and kidney and also reduce the BGL and control the total lipid in type 1 diabetes condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.